Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions

Drug Safety

Volumn 32, Issue 2, 2009, Pages 99-110

  Hauben, Manfred ^a,b,c,d,e   Aronson, Jeffrey K ^f  

^a PFIZER INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MINOXIDIL; ROFECOXIB; TOPIRAMATE;

ALOPECIA; ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HARM REDUCTION; HUMAN; MEDICATION ERROR; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUTOMATIC DATA PROCESSING; CAUSALITY; COMMUNICATION; GOVERNMENT AGENCIES; HEALTH SYSTEMS AGENCIES; HUMANS; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 60749099873     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932020-00003     Document Type: Review

References (33)

1. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28 (10): 851-70
2. Aronson JK, Ferner RE. Clarification of terminology in medication errors: definitions and classification. Drug Saf 2006; 29 (11): 1011-22
3. Lindquist M. The need for definitions in pharmacovigilance. Drug Saf 2007; 30 (10): 825-30
4. Hauben M, Reich L. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision its use. Eur J Clin Pharmacol 2005; 61: 479-80
5. Cobert BL, Biron P. Pharmacovigilance from A to Z: adverse drug event surveillance. Oxford: Blackwell Science, 2002: 191-2
6. Hauben M, Madigan D, Gerrits C, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4: 929-48
7. Cohen A. Should we tolerate tolerability as an objective in early drug development? Br J Clin Pharmacol 2007; 64: 249-52
8. Oxford English Dictionary [online]. Available from URL: http://ezproxy.ouls.ox.ac.uk:2118/entrance.dtl [Accessed 2008 Nov 13]
9. Brinker A. Use of a spontaneous adverse drug events data base for identification of unanticipated drug benefits. Clin Pharmacol Ther 2002; 71: 99-102
10. Hulbert JR. Dictionaries: British and American. London: Andre Deutsch, 1955: 68-77
11. Morton HC. The story of Webster's third: Philip Gove's controversial dictionary and its critics. Cambridge: Cambridge University Press, 1994
12. Silva P. Time and meaning: sense and definition in the OED. In: Mugglestone L, editor. Lexicography and the OED: pioneers in the untrodden forest. Oxford: Oxford University Press, 2000: 77-95
13. Trench RC. On some deficiencies in our English dictionaries, the substance of 2 papers. 2nd ed. London: J.W. Parker, 1860: 72
14. Irwin TH. Aristotle's first principles. Oxford: Oxford University Press, 1988; 61-4
15. Definition: signal. Webster's online dictionary [online]. Available from URL: http://www.websters-online-dictionary.org/definition/signal [Accessed 2008 Dec 10]
16. Weaver W, Shannon CE. The mathematical theory of communication. Urbana (IL): University of Illinois Press, 1949
17. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions [online]. Available from URL: http://whqlibdoc.who.int/hq/2002/WHO-EDM-QSM-2002.2.pdf [Accessed 2008 Nov 13]
18. Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-65
19. CIOMS Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: WHO, 1998
20. CIOMS Working Group VI. Management of safety information from clinical trials. Geneva: WHO, 2005
21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005 [online]. Available from URL: http://www.fda.gov/cder/guidance/index.htm [Accessed 2008 Nov 13]
22. Metters J. Report of an independent review of access to the yellow card scheme. London: The Stationery Office, 2004 [online]. Available from URL: http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/ con2015008.pdf [Accessed 2008 Nov 13]
23. Coulter DM. The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf 2000; 9: 273-80
24. Girard M. Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacol 1987; 23: 73-9
25. Girard M. Oral provocation: limitations. Semin Dermatol 1989; 8: 192-5
26. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 332: 1267-9
27. Hauben M, Reich L, Safety related drug-labelling changes: findings from two data mining algorithms [published erratum appears in Drug Saf 2006; 29 (12): 1192]. Drug Saf 2004; 27 (10): 735-44
28. Aronson JK, Loke Y, Derry S. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol 2002; 16: 49-56
29. Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 2008; 22: 127-40
30. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-62
31. Aronson JK. The NSAID roller coaster: more about rofecoxib. Br J Clin Pharmacol 2006; 62: 257-9
32. Hauben M, Reich L, Chung S. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur J Clin Pharmacol 2004; 60: 747-50
33. Eudravigilance Expert Working Group. Guideline on the use of statistical signal detection methods in the Eudravigilance Data Analysis System. London, 16 Nov 2006 [online]. Available from URL: http://eudravigilance.emea.europa.eu/ human/docs/10646406en.pdf [Accessed 2008 Nov 13]